Credit: Getty Images. A systematic review evaluated current and investigational intravesical and systemic therapies for NMIBC after BCG failure, including chemotherapy, immunotherapy, combination ...
HER2 overexpression in patients with nonmuscle-invasive bladder cancer independently predicts worse response to intravesical BCG therapy. HER2 expression can be used to predict outcomes after ...
SAN DIEGO -- The use of sequential intravesical gemcitabine and docetaxel appeared effective and well tolerated in patients with high-risk non-muscle invasive bladder cancer (NMIBC) following the ...
Findings from the primary analysis of the phase 3b PATAPSCO study showed that adding durvalumab (Imfinzi) to BCG induction ...
MedPage Today on MSN
Durvalumab plus BCG cut early recurrence of high-risk bladder cancer
POTOMAC data support a year's worth of immuontherapy paired with BCG induction and mainten ...
An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results